stavudine extended-release, lamivudine, efavirenz — Competitive Intelligence Brief

stavudine extended-release, lamivudine, efavirenz (stavudine extended-release, lamivudine, efavirenz) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: NRTI and NNRTI combination. Area: Infectious Disease.

phase 3 NRTI and NNRTI combination HIV reverse transcriptase Infectious Disease Small molecule

Target snapshot

stavudine extended-release, lamivudine, efavirenz (stavudine extended-release, lamivudine, efavirenz) — Bristol-Myers Squibb. Stavudine extended-release, lamivudine, and efavirenz work together to inhibit viral replication by targeting the HIV reverse transcriptase enzyme and the HIV non-nucleoside reverse transcriptase inhibitor binding site.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
stavudine extended-release, lamivudine, efavirenz TARGET	stavudine extended-release, lamivudine, efavirenz	Bristol-Myers Squibb	phase 3	NRTI and NNRTI combination	HIV reverse transcriptase
Atripla or Stribild	Atripla or Stribild	Fred Hutchinson Cancer Center	marketed	Antiretroviral combination therapy (NRTI/NNRTI or INSTI-based)	HIV reverse transcriptase, HIV integrase
DOR/DTG/3TC	DOR/DTG/3TC	Insel Gruppe AG, University Hospital Bern	marketed	Antiretroviral combination (NNRTI + INSTI + NRTI)	HIV reverse transcriptase, HIV integrase
JULUCA	JULUCA	ViiV Healthcare	marketed	Antiretroviral combination (integrase inhibitor + NNRTI)	HIV integrase and HIV reverse transcriptase
Standard Triple	Standard Triple	University of Alberta	marketed	Antiretroviral combination therapy	HIV reverse transcriptase, HIV protease (depending on formulation)
First-line Antiretroviral Therapy	First-line Antiretroviral Therapy	UPECLIN HC FM Botucatu Unesp	marketed	Antiretroviral combination therapy (NRTI/NNRTI/PI/INSTI)	HIV reverse transcriptase, HIV protease, HIV integrase (depending on regimen components)
Atazanavir, ritonavir, lamivudine	Atazanavir, ritonavir, lamivudine	Catholic University of the Sacred Heart	marketed	Antiretroviral combination (protease inhibitor + NRTI)	HIV protease, HIV reverse transcriptase

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (NRTI and NNRTI combination class)

1. Bristol-Myers Squibb · 1 drug in this class